Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs): simple drugs with a complex mechanism of action?
about
Understanding the Impact of ErbB Activating Events and Signal Transduction on Antigen Processing and Presentation: MHC Expression as a Model.Suppression of MicroRNA-7 (miR-7) Biogenesis by Nuclear Factor 90-Nuclear Factor 45 Complex (NF90-NF45) Controls Cell Proliferation in Hepatocellular CarcinomaSequence-specific peptide aptamers, interacting with the intracellular domain of the epidermal growth factor receptor, interfere with Stat3 activation and inhibit the growth of tumor cells.Multiple platform assessment of the EGF dependent transcriptome by microarray and deep tag sequencing analysisp53 in cell invasion, podosomes, and invadopodiaERBB2 juxtamembrane domain (trastuzumab binding site) gene mutation is a rare event in invasive breast cancers overexpressing the ERBB2 gene.A systems biology-based classifier for hepatocellular carcinoma diagnosis.Mechanism targeted discovery of antitumor marine natural products.Targeting the EGFR signaling pathway in cancer therapy.Time-resolved fluorescence resonance energy transfer (TR-FRET) to analyze the disruption of EGFR/HER2 dimers: a new method to evaluate the efficiency of targeted therapy using monoclonal antibodiesA peptide antigen derived from EGFR T790M is immunogenic in non‑small cell lung cancerPhotodynamic anti-cancer effects of fullerene [C₆₀]-PEG complex on fibrosarcomas preferentially over normal fibroblasts in terms of fullerene uptake and cytotoxicity.Microbead arrays for the analysis of ErbB receptor tyrosine kinase activation and dimerization in breast cancer cellsEpidermal growth factor receptor tyrosine kinase inhibitors in late stage clinical trials.Small molecule epidermal growth factor receptor tyrosine kinase inhibitors: an overview.Epidermal growth factor receptor inhibitors in cancer treatment.Distinct epithelial growth factor receptor mutation profile in non-small-cell lung cancer patients from the Xuanwei area of ChinaEGFR ligand switch in late stage prostate cancer contributes to changes in cell signaling and bone remodeling.HER2 overexpression reverses the relative resistance of EGFR-mutant H1975 cell line to gefitinibEGF receptor-targeted therapy in non-small-cell lung cancer: role of germline polymorphisms in outcome and toxicity.SV40 virus-like particles as an effective delivery system and its application to a vaccine carrier.Epidermal growth factor receptor inhibitors in non-small-cell lung cancer.Epidermal growth factor receptor tyrosine-kinase inhibitor treatment resistance in non-small cell lung cancer: biological basis and therapeutic strategies.Current adjuvant therapeutic approaches for pancreatic cancer.The Potential of panHER Inhibition in Cancer.Antitumor effect in medulloblastoma cells by gefitinib: Ectopic HER2 overexpression enhances gefitinib effects in vivo.EGFR is phosphorylated at Ty845 in hepatocellular carcinoma.The effect of ZD1839 (Iressa), an epidermal growth factor receptor tyrosine kinase inhibitor, in combination with cisplatin, on apoptosis in SCC-15 cells.Integrin alpha5/beta1 expression mediates HER-2 down-regulation in colon cancer cells.Simultaneous inhibition of epidermal growth factor receptor (EGFR) signaling and enhanced activation of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) receptor-mediated apoptosis induction by an scFv:sTRAIL fusion protein with speciHER2 signaling enhances 5'UTR-mediated translation of c-Myc mRNA.Inhibition of proliferation and induction of apoptosis in breast cancer cells by the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor ZD1839 ('Iressa') is independent of EGFR expression level.Differential radiosensitisation by ZD1839 (Iressa), a highly selective epidermal growth factor receptor tyrosine kinase inhibitor in two related bladder cancer cell lines.Inhibitors of epidermoid growth factor receptor suppress cell growth and enhance chemosensitivity of nasopharyngeal cancer cells in vitro.Gefitinib inhibits M2-like polarization of tumor-associated macrophages in Lewis lung cancer by targeting the STAT6 signaling pathway.Combination Strategies Using EGFR-TKi in NSCLC Therapy: Learning from the Gap between Pre-Clinical Results and Clinical Outcomes.Gefitinib or lapatinib with foretinib synergistically induce a cytotoxic effect in melanoma cell lines.Synthesis, antiproliferative activity, and molecular docking studies of curcumin analogues bearing pyrazole ring
P2860
Q27691330-B56F5C9C-6594-4BBB-89D3-1EFC4F297D1FQ28392330-58BA4FCC-42BA-4041-8A6F-B8E75361F678Q30958440-61FEE093-1D6B-48EB-A669-0C2E6A5A743FQ31020252-8966883A-29B4-436E-99A2-E3015AAEF6AEQ33358202-06AFFC06-7B80-49FA-9590-DF3D268ECA8BQ33875241-60416AF8-AB7B-49E7-9DD4-AD17AFD9FA53Q33987671-FE504742-C594-4A2F-8574-CC6408EA698CQ34012630-063BA3AA-DC46-4DDD-B846-221F2CB10836Q34246558-AD01808B-1482-472F-9618-675F46C2F063Q34719632-3DE3916A-34BB-4508-8D68-11E4C88DC9EFQ34775850-4C8069BD-B534-4E0F-9F0C-295DFC475BD8Q35086859-8A0E5FED-5FCF-44B5-A5A6-3D56BE2946ABQ35379924-BBB6FD97-8B98-44C1-8497-4C84D393CFC3Q35602676-656C7106-1463-41FC-9F32-F9DD9AEEDBDDQ36028642-7D55AD6D-2DD2-4AFD-A009-3D1CDE0B265CQ36429442-99E8A188-07C9-46DD-88AB-4301AE42C74CQ36825159-839A75C5-5372-47CD-882A-01F99D3FF1A4Q37397897-F28BA20B-52ED-4934-8F3C-51F7ECE67890Q37582387-02FFB54A-5EB5-460F-954C-7CA5EC2AF139Q38034817-9C737509-51E3-4809-A491-DB98A040719CQ38081973-E9A60118-01DF-495B-860B-3390BB539822Q38088756-15065AC9-F8E4-4B5D-9CDD-48D51208BDE7Q38168795-4452F2C7-1EB4-48DA-9870-53F28E87C1EDQ38321245-7213288B-3F42-4598-A36A-34421E57B7C3Q38352587-75FCABE4-3B7E-431A-AF32-1F275FA9A9F4Q39912369-2CD9FDCC-6B56-420D-8C76-47EA965CF2DDQ40238980-CD8F8EC0-7C11-4703-9C60-FB57FAB51659Q40432929-C0B9F0D2-A756-4173-ACD1-02ED30F83C36Q40448412-7DF5F80D-B467-49ED-9869-2D22C1A62185Q40472879-35FAB771-AE7F-490B-BB26-CA9CC1A9971DQ40557274-8C7C0D6B-2163-4953-A2CF-A978788D7AEDQ40619039-62ACE84A-76EF-412A-A3A0-1411DF7111F1Q41778604-BDF4FE02-DF77-4615-8C30-88CC23995CEFQ46613450-552AFBD2-33D1-4648-9EA8-324A02EC3449Q50097060-32918754-7697-4088-8A66-357343FEB246Q50345931-6E2959B0-6074-42C9-BE91-31CB4FA36C2FQ53688956-92E1B317-5F95-4A50-B7EA-F3B2CD115B4EQ56780551-544E7AE9-3F31-4FE4-837B-67639964DDC2
P2860
Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs): simple drugs with a complex mechanism of action?
description
2003 nî lūn-bûn
@nan
2003 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Epidermal growth factor recept ...... a complex mechanism of action?
@ast
Epidermal growth factor recept ...... a complex mechanism of action?
@en
type
label
Epidermal growth factor recept ...... a complex mechanism of action?
@ast
Epidermal growth factor recept ...... a complex mechanism of action?
@en
prefLabel
Epidermal growth factor recept ...... a complex mechanism of action?
@ast
Epidermal growth factor recept ...... a complex mechanism of action?
@en
P2093
P356
P1476
Epidermal growth factor recept ...... a complex mechanism of action?
@en
P2093
Antonella De Luca
Monica R Maiello
Nicola Normanno
P356
10.1002/JCP.10194
P577
2003-01-01T00:00:00Z